<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828124</url>
  </required_header>
  <id_info>
    <org_study_id>CA015-003</org_study_id>
    <nct_id>NCT02828124</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer</brief_title>
  <official_title>A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of BMS-986183 in
      patients with liver cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business objectives have changed
  </why_stopped>
  <start_date type="Actual">August 23, 2016</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events at Its Worst Grade</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events at Its Worst Grade</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Evaluated by comparing the incidence of Serious Adverse Events (SAEs) among subjects using their assigned treatment for at least one day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events Leading to Discontinuation</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Evaluated by comparing the incidence of Adverse Events leading to discontinuation among subjects using their assigned treatment for at least one day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events Leading to Death</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Evaluated by comparing the incidence of Adverse Events leading to death among subjects using their assigned treatment for at least one day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Laboratory Test Toxicity Grade Shifting From Baseline</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Defined as BOR designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. CR or PR determinations included in the BOR assessment must be confirmed by a second scan performed no less than 4 weeks after the criteria for response are first met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Defined as the total number of subjects whose BOR is either a CR or PR divided by the total number of subjects in the population of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first. For those subjects who remain alive and have not progressed or received subsequent therapy, DoR will be censored on the date of last tumor assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Defined as the time from the first dose of study drug to the date of the first objective documentation of tumor progression or death due to any cause. Subjects who did not progress nor died will be censored on the date of their last tumor assessment. Subjects who did not have any on-study tumor assessments will be censored on the date of the first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate at Week 't'</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>Defined as the proportion of subjects who remain progression free and surviving at 't' weeks (t=12, 24, 36, etc). The proportion will be calculated by the product-limit method (Kaplan-Meier [K-M] estimate) which takes into account censored data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>From first does up to approximately 24 months</time_frame>
    <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time 0 to T of the Last Quantifiable Concentration [AUC(0-T)]</measure>
    <time_frame>First does up to appromimately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(0-T)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(TAU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the End of a Dosing Interval (Ctau)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Observed Concentration, Including Predose Concentrations and Ctau (Ctrough)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CLT)</measure>
    <time_frame>First dose to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by CLT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady-state (Vss)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of Terminal Phase (Vz)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>(to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index; Ratio of Ctau at Steady-state to Ctau After the First Dose (AI_Ctau)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Ctau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)]</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_AUC(TAU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration Over a Dosing Interval Calculated by Dividing AUC(TAU) at Steady State by Tau (Css,Ave)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Css,avg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (T-HALF)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by T-HALF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QTcF (Î”QTcF) From Baseline</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <description>To assess the effect of dosage regimen and exposure [active ADC and unconjugated tubulysin] of BMS-986183 as monotherapy on the QT interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Positive Anti-drug Antibody (ADA)</measure>
    <time_frame>First dose up to approximately 24 months</time_frame>
    <description>The immunogenicity of BMS-986183 (as monotherapy and in combination with nivolumab) will be measured by assessment of the presence or absence of specific ADA to BMS-986183. The incidence of positive ADA will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986183</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_label>Dose Escalation Monotherapy</arm_group_label>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
    <arm_group_label>Dose Expansion Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>specified dose on specified days</description>
    <arm_group_label>Dose Escalation Combination Therapy</arm_group_label>
    <arm_group_label>Dose Expansion Combination Therapy</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Must have advanced liver cancer that cannot be treated with surgery or other local
             methods

          -  Liver cancer is confirmed by a microscopic examination of tissue

          -  Liver disease is classified as 'A' by a standard method called Child-Pugh score

          -  Daily living abilities are classified as '0 or 1' by a standard method from the
             Eastern Cooperative Oncology Group (ECOG)

          -  Women must use contraception

        Exclusion Criteria:

          -  Prior liver transplant

          -  Increase in blood pressure in some of the veins entering the liver

          -  Cancer that has spread to the brain or the layers of tissue that cover the brain or
             spinal cord

          -  Infection with both hepatitis B and C, both hepatitis D and B, infection with HIV, or
             other infections

          -  Disease of the heart or blood vessels around the heart

          -  Active cancers within the last 2 years

          -  No more than 2 prior systemic treatments or other investigational agents except
             PD-1/PD-L1 or Ipilimumab (Part 2)

          -  Currently on anti-platelet or anti-coagulation therapy

          -  Radiotherapy within 4 weeks of treatment

          -  Any major allergies

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <results_first_submitted>January 7, 2019</results_first_submitted>
  <results_first_submitted_qc>January 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02828124/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02828124/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 10 subjects were treated in this study. All 10 subjects were enrolled in BMS-986183 escalation (Part 1)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BMS-986183 3 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="P2">
          <title>BMS-986183 9 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="P3">
          <title>BMS-986183 18 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="P4">
          <title>BMS-986183 36 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE Unrelated to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated paritcipants</population>
      <group_list>
        <group group_id="B1">
          <title>BMS-986183 3 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="B2">
          <title>BMS-986183 9 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="B3">
          <title>BMS-986183 18 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="B4">
          <title>BMS-986183 36 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All treated participants</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="B2" value="67.5" spread="4.9"/>
                    <measurement group_id="B3" value="57.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="B4" value="49.5" spread="8.6"/>
                    <measurement group_id="B5" value="54.5" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events at Its Worst Grade</title>
        <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events at Its Worst Grade</title>
          <description>Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events at Its Worst Grade</title>
        <description>Evaluated by comparing the incidence of Serious Adverse Events (SAEs) among subjects using their assigned treatment for at least one day.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events at Its Worst Grade</title>
          <description>Evaluated by comparing the incidence of Serious Adverse Events (SAEs) among subjects using their assigned treatment for at least one day.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events Leading to Discontinuation</title>
        <description>Evaluated by comparing the incidence of Adverse Events leading to discontinuation among subjects using their assigned treatment for at least one day.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Leading to Discontinuation</title>
          <description>Evaluated by comparing the incidence of Adverse Events leading to discontinuation among subjects using their assigned treatment for at least one day.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events Leading to Death</title>
        <description>Evaluated by comparing the incidence of Adverse Events leading to death among subjects using their assigned treatment for at least one day.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Leading to Death</title>
          <description>Evaluated by comparing the incidence of Adverse Events leading to death among subjects using their assigned treatment for at least one day.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Laboratory Test Toxicity Grade Shifting From Baseline</title>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Laboratory Test Toxicity Grade Shifting From Baseline</title>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response (BOR)</title>
        <description>Defined as BOR designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. CR or PR determinations included in the BOR assessment must be confirmed by a second scan performed no less than 4 weeks after the criteria for response are first met.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response (BOR)</title>
          <description>Defined as BOR designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. CR or PR determinations included in the BOR assessment must be confirmed by a second scan performed no less than 4 weeks after the criteria for response are first met.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Defined as the total number of subjects whose BOR is either a CR or PR divided by the total number of subjects in the population of interest</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Defined as the total number of subjects whose BOR is either a CR or PR divided by the total number of subjects in the population of interest</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR)</title>
        <description>Defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first. For those subjects who remain alive and have not progressed or received subsequent therapy, DoR will be censored on the date of last tumor assessment</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR)</title>
          <description>Defined as the time between the date of first response and the subsequent date of objectively documented disease progression or death, whichever occurs first. For those subjects who remain alive and have not progressed or received subsequent therapy, DoR will be censored on the date of last tumor assessment</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Defined as the time from the first dose of study drug to the date of the first objective documentation of tumor progression or death due to any cause. Subjects who did not progress nor died will be censored on the date of their last tumor assessment. Subjects who did not have any on-study tumor assessments will be censored on the date of the first dose of study drug.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Defined as the time from the first dose of study drug to the date of the first objective documentation of tumor progression or death due to any cause. Subjects who did not progress nor died will be censored on the date of their last tumor assessment. Subjects who did not have any on-study tumor assessments will be censored on the date of the first dose of study drug.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS Rate at Week 't'</title>
        <description>Defined as the proportion of subjects who remain progression free and surviving at 't' weeks (t=12, 24, 36, etc). The proportion will be calculated by the product-limit method (Kaplan-Meier [K-M] estimate) which takes into account censored data</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>PFS Rate at Week 't'</title>
          <description>Defined as the proportion of subjects who remain progression free and surviving at 't' weeks (t=12, 24, 36, etc). The proportion will be calculated by the product-limit method (Kaplan-Meier [K-M] estimate) which takes into account censored data</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax)</title>
        <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Cmax</description>
        <time_frame>From first does up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax)</title>
          <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Cmax</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Observed Concentration (Tmax)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Tmax.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration (Tmax)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Tmax.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time 0 to T of the Last Quantifiable Concentration [AUC(0-T)]</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(0-T)]</description>
        <time_frame>First does up to appromimately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time 0 to T of the Last Quantifiable Concentration [AUC(0-T)]</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(0-T)]</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]</title>
        <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(TAU).</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]</title>
          <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AUC(TAU).</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration at the End of a Dosing Interval (Ctau)</title>
        <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration at the End of a Dosing Interval (Ctau)</title>
          <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Observed Concentration, Including Predose Concentrations and Ctau (Ctrough)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by (Ctrough)</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Observed Concentration, Including Predose Concentrations and Ctau (Ctrough)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by (Ctrough)</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Clearance (CLT)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by CLT</description>
        <time_frame>First dose to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CLT)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by CLT</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution at Steady-state (Vss)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vss</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Steady-state (Vss)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vss</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution of Terminal Phase (Vz)</title>
        <description>(to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vz.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution of Terminal Phase (Vz)</title>
          <description>(to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Vz.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Cmax.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index; Ratio of Cmax at Steady-state to Cmax After the First Dose (AI_Cmax)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Cmax.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index; Ratio of Ctau at Steady-state to Ctau After the First Dose (AI_Ctau)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Ctau.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index; Ratio of Ctau at Steady-state to Ctau After the First Dose (AI_Ctau)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_Ctau.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)]</title>
        <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_AUC(TAU).</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Index; Ratio of AUC(TAU) at Steady-state to AUC(TAU) After the First Dose [AI_AUC(TAU)]</title>
          <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by AI_AUC(TAU).</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration Over a Dosing Interval Calculated by Dividing AUC(TAU) at Steady State by Tau (Css,Ave)</title>
        <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Css,avg.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration Over a Dosing Interval Calculated by Dividing AUC(TAU) at Steady State by Tau (Css,Ave)</title>
          <description>To characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by Css,avg.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (T-HALF)</title>
        <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by T-HALF.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (T-HALF)</title>
          <description>to characterize the PK of the total antibody [unconjugated antibody + antibody conjugated to tubulysin or antibody conjugated to any tubulysin metabolites], active ADC [antibody conjugated to tubulysin], and unconjugated tubulysin) of BMS-986183 as monotherapy and in combination with nivolumab will be measured by T-HALF.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in QTcF (Î”QTcF) From Baseline</title>
        <description>To assess the effect of dosage regimen and exposure [active ADC and unconjugated tubulysin] of BMS-986183 as monotherapy on the QT interval.</description>
        <time_frame>Baseline up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in QTcF (Î”QTcF) From Baseline</title>
          <description>To assess the effect of dosage regimen and exposure [active ADC and unconjugated tubulysin] of BMS-986183 as monotherapy on the QT interval.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Positive Anti-drug Antibody (ADA)</title>
        <description>The immunogenicity of BMS-986183 (as monotherapy and in combination with nivolumab) will be measured by assessment of the presence or absence of specific ADA to BMS-986183. The incidence of positive ADA will be calculated.</description>
        <time_frame>First dose up to approximately 24 months</time_frame>
        <population>The study was terminated and data is not reported for privacy reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS-986183 3 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O2">
            <title>BMS-986183 9 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O3">
            <title>BMS-986183 18 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
          <group group_id="O4">
            <title>BMS-986183 36 mg</title>
            <description>Dose escalation in combination with Nivolumab</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Positive Anti-drug Antibody (ADA)</title>
          <description>The immunogenicity of BMS-986183 (as monotherapy and in combination with nivolumab) will be measured by assessment of the presence or absence of specific ADA to BMS-986183. The incidence of positive ADA will be calculated.</description>
          <population>The study was terminated and data is not reported for privacy reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose up to approximately 24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BMS-986183 ESC 3 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="E2">
          <title>BMS-986183 ESC 9 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="E3">
          <title>BMS-986183 ESC 18 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
        <group group_id="E4">
          <title>BMS-986183 ESC 36 mg</title>
          <description>Dose escalation in combination with Nivolumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period â‰¤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Phase 1/2 Study of BMS-986183 in Subjects with Advanced Hepatocellular Carcinoma</name_or_title>
      <organization>Bristol Myers-Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

